Future of Allergic Rhinitis Management
A Synopsis
DOI:
https://doi.org/10.58931/cait.2022.2s0546Abstract
Allergic rhinitis (AR) is an inflammatory condition affecting the nasal mucosa mediated byimmunoglobulin-E (IgE). It impacts an estimated 25% of Canadians, of whom most report inadequatesymptom control despite treatment as well as highrates of asthma comorbidity. First line pharmacologic options include non-sedating, 2nd generation oral H1-antihistamine (OAH) and/or intranasal corticosteroid (INCS) therapeutic agents. Allergen immunotherapy (AIT) is a possible treatment option for moderate-to-severe disease which is uncontrolled with the use of first-line therapies or for those patients wishing to avoid pharmacologic intervention. However, patient education, engagement, and empowerment are central to optimal clinica outcomes. This supplement summarizes the literature to present the future of AR management.
References
Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy: European Journal of Allergy and Clinical Immunology. Published online 2008. doi:10.1111/j.1398-9995.2007.01620.x
Keith PK, Desrosiers M, Laister T, Schellenberg RR, Waserman S. The burden of allergic rhinitis (AR) in Canada: perspectives of physicians and patients. Allergy, Asthma and Clinical Immunology. 2012;8(1):7. doi:10.1186/1710-1492-8-7
Bousquet J, Schünemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70-80.e3. doi:10.1016/J.JACI.2019.06.049
Bousquet J, Hellings PW, Agache I, et al. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clinical and Translational Allergy. 2016;6(1):1-14. doi:10.1186/S13601-016-0137-4/FIGURES/3
Menditto E, Costa E, Midão L, et al. Adherence to treatment in allergic rhinitis using mobile technology. The MASK Study. Clinical & Experimental Allergy. 2019;49(4):442-460. doi:10.1111/CEA.13333
Bédard A, Basagaña X, Anto JM, et al. Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. Journal of Allergy and Clinical Immunology. 2019;144(1):135-143.e6. doi:10.1016/J.JACI.2019.01.053
Santo K, Richtering SS, Chalmers J, Thiagalingam A, Chow CK, Redfern J. Mobile phone apps to improve medication adherence: A systematic stepwise process to identify high-quality apps. JMIR Mhealth Uhealth. 2016;4(4). doi:10.2196/mhealth.6742
Berger W, Bousquet J, Fox AT, et al. MP-AzeFlu is more effective than fluticasone propionate for the treatment of allergic rhinitis in children. Allergy. 2016;71(8):1219-1222. doi:10.1111/ALL.12903
Berger WE, Shah S, Lieberman P, et al. Long-term, Randomized Safety Study of MP29-02 (a Novel Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate in an Advanced Delivery System) in Subjects With Chronic Rhinitis. The Journal of Allergy and Clinical Immunology: In Practice. 2014;2(2):179-185. doi:10.1016/J.JAIP.2013.09.019
Agache I, Doros IC, Leru PM, Bucur I, Poenaru M, Sarafoleanu C. MP-AzeFlu provides rapid and effective allergic rhinitis control: results of a non-interventional study in Romania. Rhinology. 2018;56(1):33-41. doi:10.4193/RHIN16.278
Haahr PA, Jacobsen C, Christensen ME. MP-AzeFlu provides rapid and effective allergic rhinitis control: results of a non-interventional study in Denmark. International Forum of Allergy & Rhinology. 2019;9(4):388-395. doi:10.1002/ALR.22258
Stjärne P, Strand V, Theman K, Ehnhage A. Control of allergic rhinitis with MP-AzeFlu: a noninterventional study of a Swedish cohort. Rhinology. 2019;57(4):279-286. doi:10.4193/RHIN18.028
Klimek L, Bachert C, Stjärne P, et al. MP-AzeFlu provides rapid and effective allergic rhinitis control in real life: A pan-European study. Allergy Asthma Proc. 2016;37(5):376-386. doi:10.2500/AAP.2016.37.3979
Price D, Klimek L, Gálffy G, et al. Allergic rhinitis and asthma symptoms in a real-life study of MP-AzeFlu to treat multimorbid allergic rhinitis and asthma. Clinical and Molecular Allergy. Published online 2020. doi:10.1186/s12948-020-00130-9
de Jong HJI, Voorham J, Scadding GK, et al. Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with allergic rhinitis and asthma in UK primary care. World Allergy Organization Journal. Published online 2020. doi:10.1016/j.waojou.2020.100490
Gross GN, Amar NJ, Fernando N, Caracta CF, Tantry SK. Olopatadine/Mometasone Combination Nasal Spray for the Treatment of Seasonal Allergic Rhinitis: A Pooled Analysis of Efficacy and Safety. Journal of Allergy and Clinical Immunology. Published online 2019. doi:10.1016/j.jaci.2018.12.191
Biedermann T, Kuna P, Panzner P, et al. The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial. Journal of Allergy and Clinical Immunology. 2019;143(3):1058-1066.e6. doi:10.1016/J.JACI.2018.12.1001
Ellis AK, Gagnon R, Hammerby E, Shen J, Gosain S. Sublingual immunotherapy tablet: a cost-minimizing alternative in the treatment of tree pollen-induced seasonal allergic rhinitis in Canada. Allergy, Asthma and Clinical Immunology. 2021;17(1):1-9. doi:10.1186/S13223-021-00565-Y/FIGURES/1
Ellis AK, Gagnon R, Hammerby E, Lau A. Sublingual immunotherapy tablet for the treatment of house dust mite allergic rhinitis in Canada: An alternative to minimize treatment costs? Allergy, Asthma and Clinical Immunology. 2019;15(1):1-9. doi:10.1186/S13223-019-0344-3/FIGURES/1
Maloney J, Berman G, Gagnon R, et al. Sequential Treatment Initiation with Timothy Grass and Ragweed Sublingual Immunotherapy Tablets Followed by Simultaneous Treatment Is Well Tolerated. The Journal of Allergy and Clinical Immunology: In Practice. 2016;4(2):301-309.e2. doi:10.1016/J.JAIP.2015.11.004
Ellis AK, Frankish CW, Armstrong K, et al. Persistence of the clinical effect of grass allergen peptide immunotherapy after the second and third grass pollen seasons. Journal of Allergy and Clinical Immunology. Published online 2020. doi:10.1016/j.jaci.2019.09.010
Weinstein SF, Katial R, Jayawardena S, et al. Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma. Journal of Allergy and Clinical Immunology. Published online 2018. doi:10.1016/j.jaci.2017.11.051
Busse WW, Maspero JF, Lu Y, et al. Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis. Annals of Allergy, Asthma and Immunology. Published online 2020. doi:10.1016/j.anai.2020.05.026
The Efficacy of Preseasonal Omalizumab Treatment – Full Text View – ClinicalTrials.gov. Accessed April 21, 2022. https://www.clinicaltrials.gov/ct2/show/NCT04489121
Special Drug Use Observational Study of Xolair in Patients With Severe to Most Severe Seasonal Allergic Rhinitis Aged ≥ 12 Years and < 18 Years Whose Symptoms Were Inadequately Controlled Despite to Conventional Therapies – Full Text View – ClinicalTrials.gov. Accessed April 21, 2022. https://clinicaltrials.gov/ct2/show/NCT04648930
